SLE
Super League Enterprise Inc.
Mentions (24Hr)
0.00% Today
Reddit Posts
Watchlist for the end of November and into December: $SLE $LIFFF $SONG
Watchlist for the end of November and into December: $SLE $LIFFF $SONG
Mentions
$SLE is going to pump overnight 1.5 soon!
Bought some SLE with the SI murmurs going around, and Im already have 5% so that's cool.
$XPON / $SLE hoping for both to squeeze
In on SLE, won’t take much to move this one
$SLE 500% borrow rate on Fintel and volume is thin
Do you think SLE stock reach the levels of the beginning of the year at a point?
After a reverse split, after dilution, before news hits. Still around $1 or over. I'm looking at SLE right now.
https://www.stocktitan.net/news/SLE/super-league-regains-full-compliance-with-nasdaq-listing-p9w9vm1fx6iq.html
https://www.stocktitan.net/news/SLE/super-league-regains-full-compliance-with-nasdaq-listing-p9w9vm1fx6iq.html
9:11 MM. 2 US Press Release .. US Press Release Super Leaque Regains Full Compliance with Nasdag Listing Requirements SLE Oct 29, 2025 SANTA MONICA, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) - Super League SLE (the Company"), a leader in playable media trusted by global brands to reach and activate gaming audiences through playable ads and gamified content, today announced that on October 28, 2025, the Company received a written notice from The Nasdaq Stock Marke "Nasdaq") informing Super League that it has regained compliance with Nasdaq Listing Rule 5550(b), and that the Company is in compliance with all applicable continued listing requirements. Accordingly, the hearing before the Hearings Panel scheduled to take place on November 1, 2025, has been cancelled. As this matter is now closed the Company's ordinary shares will continue to trade uninterrupted on Nasdaq under the ticker "SLE". About Super League Super League (Nasdaq: SLE) is redefining how brands connect with consumers through the ower of playable media. The company creates moments that matter by placing brands lirectly in the path of play through playable ads and gamified content across mobile, web CTV, social, and the world's largest immersive gaming platforms. Powered by proprietar) echnologies, an award-winning development studio, and a vast network of native creators Super League enables brands to stand out culturally, inspire loyalty, and drive measurable mpact in today's attention-driven economy. For more information, visit superleague.com Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of Sectio 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchango Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 "orward Looking Statements can be identified by words such as "anticipate," "intend," "plan goal, "seek," "believe," "project," "estimate" "expect," "strategy," "future," "likely" "may, "should,""will" and similar references to future periods. Forward-looking statements include all statements other than statements of historical fact, including, without limitation, a statements regarding the private placement, including expected proceeds, Super League's bility to maintain compliance with the Listing Rules of the Nasdaq Capital Marke statements regarding expected operating results and financial performance (including the Company's commitment to and ability to achieve Adjusted EBITDA-positive results in 4 strategic transactions and partnerships, and capital structure, liquidity, and financing activities. These statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which the Company operates, managements current beliefs, and certain assumptions made by the Company, all of which are subject to change. "orward-looking statements are not guarantees of future performance and involve knowi and unknown risks, uncertainties, and other factors that are difficult to predict and that could cause actual results to differ materially from those expressed or implied by such 'orward-looking statements. Important factors include, but are not limited to: the Company's ability to adequately utilize the funds received recent financings; the Company: ability to execute on cost reduction initiatives and strategic transactions; customer demand and adoption trends; the timing, outcome, and enforceability of any patent applications; the ability to successfully integrate new technologies and partnerships; platform, regulator, macroeconomic and market conditions; the Company's ability to maintain compliance with Nasdaq Capital Market continued listing standards, access to, and the cost of, capital; anc the other risks and uncertainties described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, the Company's Quarterly Report on Form 10-Q for the quarters ended March 31, 2025 and Jund 30, 2025, and other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on any forward-looking statements, which speak only s of the date hereof. Except as required by law, the Company undertakes no obligation to Ipdate or revise any forward-looking statements to reflect events or circumstances afte he date of this release or to reflect the occurrence of unanticipated events Investor Relations Contact: Shannon Devine/ Mark Schwalenberg MZ North America Main: 203-741-8811 SLE@mzgroup.us (END) Dow Jones Newswires October 29, 2025 09:00 ET (13:00 GMT) The statements in this document shall not be considered as an objective or independenti explanation of the matters. Please note that this document (a) has not been prepared ir accordance with legal requirements designed to promote the independence of investment esearch, and (b) is not subject to any prohibition on dealing ahead of the dissemination o publication of investment research. Data powered by GFIS
Reuters News Super League Secures $20 Million in Oversubscribed Private Placement Offering SLE Oct 28,2025 Super League Enterprise Inc. SLE has completed its previouslv announced private placement fnancing, securing a total of $20 milion in gross proceeds following strong investor demand. The offering included shares of common stock, pre-funded warrants, and warrants to purchase common stock, and was anchored by a $1 0 million investment from Evo Fund. The company plans to use the net proceeds for working capital, general corporate purposes, debt repayment, and strategic growth initiatives. Aegis Capital Corp. acted as the exclusive placement agent for the offering. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Super League Enterprise Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9563184-en) on October 28, 2025, and is solely responsible for the information contained therein. (C) Copyright 2025- Public Technologies (PUBT) Data powered by GFIS
Options are not even available for SLE
Adicet Bio (ACET) price targets have been updated recently. Guggenheim raised their price target to $8, HC Wainwright has them at $4. Current share price $0.97 Pipeline: They consolidated their pipeline to two primary candidates which have HUGE potential. For autoimmune diseases, positive preliminary data from a Phase 1 trial was announced in October 2025. The trial includes patients with conditions such as lupus nephritis (LN), systemic lupus erythematosus (SLE), and others. Results in the LN group showed a 100% renal response rate and a generally well-tolerated safety profile. Adicet intends to discuss a Phase 2 trial with the FDA in early 2026. ADI-001 is also in a Phase 1 trial for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), focusing on mantle cell lymphoma (MCL). Note: Yes the sample size is small - this is a VERY rare space. Off-the-shelf allogeneic Car-T cell therapy has not been very successful even in phase 1 trials from other companies. Off the shelf means that it does NOT require patient-specific factors for acquiring the T Cells. They can be obtained from general population and this makes them much more readily available. The fact that they even had 100% response rate from a small phase 1 study is not common. For example, people cite Adaptimmune as a failed CAR-T company - they only had 33% response rate even in their phase 1 study, before their phase 2 fizzled out. In solid tumors, Adicet is focusing on the preclinical development of ADI-212 for metastatic castration-resistant prostate cancer (mCRPC). ADI-212 is a gene-edited gamma delta CAR T cell candidate targeting PSMA. A regulatory filing is expected in early 2026, with initial clinical data in the latter half of 2026. Financial status: **Cash runway most recently announced was $150 million, plus an additional 80 million direct offering last week (**shares and pre-funded warrants). These are getting eaten up quickly by industry investors/corporations, AND insiders. They recently got extension until April for compliance so they will want to keep this share price above $1. Chart/Insiders: Adicet Bio's stock holds buy signals from both short- and long-term Moving Averages, and a buy signal from the 3-month Moving Average Convergence Divergence (MACD). Insiders have also been positive, buying more shares than selling recently. A 5 million share insider trade was just disclosed. Outlook (personal opinion, due your own DD) - I see this as a medium term play with lots of insider and institutional buying recently, promising outlook, strong cash runway without need for further dilution, and potential catalysts from their two trials within the next 6 months.
What does it mean if SLE has a borrow rate in the 700s?
$SLE – A Pressure Cooker Setup • Float: Extremely limited, meaning even modest buying can move the price significantly. • Borrow Rate: Currently sitting at 625% APR (see attached). This is an unusually high cost of borrow, making it extremely expensive for shorts to maintain positions. When you combine a micro-float with sky-high borrow fees, you essentially have a setup where shorts are cornered. Any increase in demand could trigger aggressive covering. Not financial advice, just highlighting the math — this one has all the ingredients for a potential squeeze. And yea I used ChatGPT https://preview.redd.it/5m5jtfnt65rf1.jpeg?width=1290&format=pjpg&auto=webp&s=1c1718fab91ae38fa0515807710ac414f72e43c9
$SLE about to blow up. $100 price target and big bitcoin news
How do we feel about SLE? It had crazy numbers overnight
check out SLE then tell me what you think
I have been in SLE for a few years now. Every year they say they will be profitable within the next year. I had thousands of shares, then first reverse split hit and I was down to roughly 200. Bought more to bring my average down believing the promises of being profitable within the next year. Was up to over 2k shares and then second reverse split (20:1) hit and I’m back to less than 100 shares with an average cost of $74 and total loss of 94%. I have lost all faith jn this company and can’t justify throwing any more money at them. I will continue to hold my 81 shares until the next reverse split or until I find something to even out the loss.
Oppenheimer is a major investment firm, and their priority is delivering value to their investor base -- not the companies they cover. So I doubt they’d back something they don’t see real potential in. Just my take. That said, regardless of where the rating comes from, if Climb executes on even part of its pipeline (ITP, SLE, pMN, IgA), the upside could be big.
How is this any different from $SLE?
Synopsis Climb Bio Inc. (CLYM) is a clinical-stage biotechnology company with a robust pipeline targeting immune-mediated diseases. The company has secured FDA clearance for trials in multiple indications, including Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE). With a strong cash position expected to fund operations through 2027, Climb Bio is well-positioned to advance its clinical programs. However, investors should be mindful of the inherent risks associated with clinical-stage biotech companies, such as regulatory approvals and market competition. Market Analysis Technical Outlook: The stock is trading at $1.28, with a slight increase of $0.04 (3.18%) from the previous close. The 5-day moving average is $1.23, indicating a bullish trend. The Relative Strength Index (RSI) is 55.90, suggesting neutral momentum. The Moving Average Convergence Divergence (MACD) is positive, further supporting a bullish outlook. Risk Factors: Key risks include the uncertainties inherent in clinical trials, potential regulatory hurdles, and competition from other biotech firms. Additionally, the company's net loss of $73.9 million for the full year 2024, primarily due to acquired in-process research and development expenses, indicates ongoing financial challenges. Key Metrics: The company reported a cash position of approximately $213 million as of December 31, 2024, providing a runway through 2027. The market capitalization is $79.739 million, with shares outstanding totaling 67.58 million. The 52-week range is $1.05 to $9.21, reflecting significant volatility. Market Sentiment: Analyst sentiment is positive, with a consensus 'Buy' rating and a 12-month price target of $10, suggesting a potential upside of approximately 726%. However, the stock has experienced a decline of 82.98% over the past year, indicating market volatility and investor caution. https://preview.redd.it/wlawkjochpaf1.jpeg?width=1070&format=pjpg&auto=webp&s=d2dcae03e6bb1bff500551fdd08c6aec099f2e5b
Watch $SLE at market open. Not PM, market open. It did a 1:40 RS Friday to be effective Monday. Also $KULR finally did 1:8, so in theory it’ll be out of pennystock land unless somehow it’s shorted from the new price around $6.93 down to under $5 - I’m betting it won’t ;) Also watch $SVRE and $JFBR. $HUBC is a third low float Israeli stock. Oh dang haha…these ones! https://preview.redd.it/xusnn7u50i8f1.jpeg?width=1170&format=pjpg&auto=webp&s=a5128bd77e70fd7ee6d897fce366459deabcc627
Lol it's a top-of-the-line Zelex SLE. It's as good as it gets until AI sex robots come out. If it looks "worn out" to you it's because I've fucked it so many times in the past year.
SLE is the play for the week
$REVB, $SISI, $BURU, $SLE, $EONR $APLD it’s been nice knowing you in pennystock land. $BBAI and $HBIO will run again.
Last week I had some luck on BURU and SLE, bought some INAB for fun to test my luck... Let's see where that lands next week. Also opened a small position on REVB, cuz it reminds me of the Reverb button on my amp. Btw I always play on 11.
Anyone in SLE ? It's up 25% PM
You guys aren't going to believe this shit, but yesterday I bought BURU and it went up, today I bought SLE, guess what 😂😂😂
Sure which one? Looks like $SLE just announced an offering so that’s down today. $SUP is an aluminum wheel manufacturer that is undervalued imo. $SRM just closed a private placement so something is brewing with that company - an interesting niche making media-themed merchandise.
OTC $QNCCF ripped, looking at $SCPCF next. Still watching $DGLY and low shares. Solid plays, but not today: $SUP, $SLE, $SRM. Oil plays: $TPET, $EONR Hydrogen: $PLUG Semiconductor: $VLN
SLE Super League Announces Exclusive Partnership with AdArcade to Bring High-Performing Native Playable™ Ads to Brands and Media Agencies at Scale Across Mobile Games
Here’s my list of stocks that have potential to move (could be down, but that’s movement!): $SUP, $TRUG, $CASK, $SLE, $DFLI, maybe $OCTO.
Anyone seeing the setup with SLE? Looks like a potential squeeze brewing to me. I'm relatively new at this so take anything I say with a grain of salt because I could be wrong.
They were looking to buy a gaming company a couple years ago and there was rumors $SLE was one of them. They’re sitting on a pile of cash and many believe they need to diversify more. Since then they’ve introduced a lot of trading card stuff and crypto cards ect but they haven’t bought a gaming company yet. This would be a low risk high reward buyout imo.
Since the last rumor the market has matured a lot. Big companies like paramount,Walmart, Gucci ect have all paid millions to SLE for custom ad worlds. For example paramount hired them to make a gladiator world for the new movie. They’ve made a Walmart world, a Kraft world ect. It’s still an early market but gme getting their feet wet with this would be smart imo. Also Looks like SLE has earnings this Thursday. Just read they almost got bought by Infinite reality. they bought a 6.9% stake for now. Might wait until earnings to buy some🤷♂️
SLE Buy now, thank me later
SLE taking off 
If this sub frontal assaulted SLE we could all make some money. Check that market cap and price action
https://preview.redd.it/onk6szls3ohe1.png?width=864&format=png&auto=webp&s=4e462416bb2c4740f839733d6e67b368e841a395 $ACET: Adicet was given a FDA approval refractory Systemic Lupus erythematosus (SLE) this week but that's not the only indication that ACET is working on. This is a buy and hold stock! PT $8
News - ACET Announced FDA approval of fast track designation of its new drug Adicet Bio Inc announced today that FDA has granted fast track designation of its trial-staged new drug. Stock is trading at $1.01 a piece and the pre-market volume exploded. Below is expected from company press release- REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Feb. 5, 2025-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with refractory systemic lupus erythematosus (SLE) with extrarenal involvement. Fast Track Designation is a process designed to facilitate development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. About ADI-001 ADI-001 is an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy targeting CD20 for the treatment of autoimmune diseases. ADI-001 was granted Fast Track Designation by the FDA for the treatment of relapsed/refractory class III or class IV lupus nephritis (LN), and SLE with extrarenal involvement. The Company is advancing ADI-001 across six autoimmune indications. Patient enrollment is ongoing in the Phase 1 study evaluating ADI-001 for the treatment of LN. Patient enrollment in SLE, systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM, or myositis), and stiff person syndrome (SPS) is expected to be initiated in the first quarter of 2025. Initiation of enrollment in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is expected in the second half of 2025. In the Phase 1 GLEAN trial, ADI-001 was shown to target B-cells via an anti-CD20 CAR and demonstrated robust exposure and complete CD19+ B-cell depletion both in peripheral blood and secondary lymphoid tissue. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com. Disclaimer: The opinions expressed in this article are solely those of the OP. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE). ACET
Hi, I just found this post very interesting. I was also doing some research on this topic. The other day, Super League Enterprise (SLE) sent a letter to shareholders. Infinity Reality (IR) invested an initial 9.9% stake in SLE. I invested in SLE, because SLE can now accompany brands on their journey to Web3D through third parties and through their own websites, thanks to IR's technology (VR/AR). What is your opinion? SLEQ3-Letter [https://d1io3yog0oux5.cloudfront.net/\_75fa590e6954c24ba49fba762fcc7284/superleague/db/668/5654/shareholder\_letter/SLE+Q3%2724+Letter.pdf](https://d1io3yog0oux5.cloudfront.net/_75fa590e6954c24ba49fba762fcc7284/superleague/db/668/5654/shareholder_letter/SLE+Q3%2724+Letter.pdf)
CABA is interesting CAR-T for autoimmune. AUTL with recently approved CAR-T for ALL with potential to displace tcarteous is presenting phase 1 data on SLE in Q1 2025.
I think the MOA is different as this drug inhibits B cell activity. I agree that the results from the SLE trial didn’t look too promising but they did show a delay in time for the progression of symptoms from the disease. I think the results from the IgG4 trials were much more promising. While it might not outperform similar drugs on the market it can eat away at their market share. There’s a reason there are dozens of antidepressants on the market when most of them have similar efficacy. Some patients respond differently to different medication.
I’m failing to understand how this drug is much different from other monoclonal antibodies. Most the studies seem to be focused on treating SLE and not really showing better results compared to controls. I feel like there’s not really enough studies outside of the ones done by the pharma company promoting the drug to say this will be a popular option.
NEWS! BenevolentAI and AstraZeneca collaboration yields continued success as further novel target progressed into portfolio Home News and media Press releases and in the media BenevolentAI and AstraZeneca collaboration yields continued success as further novel target progressed into portfolio 25 Jun 2024 London, 25 June 2024: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for systemic lupus erythematosus (SLE) to its discovery portfolio through its collaboration with BenevolentAI. Second target to be selected this year from the extended collaboration with AstraZeneca, highlighting continued positive progress in the field of target identification Novel target for SLE was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca BenevolentAI’s strategic collaboration with AstraZeneca began in 2019 in idiopathic pulmonary fibrosis and chronic kidney disease, with the collaboration expanded in January 2022 to include heart failure and SLE. The success today in the extension phase of the collaboration follows the announcement last month that AstraZeneca had selected a novel heart failure target to enter its portfolio and further demonstrates how the Benevolent PlatformTM can be applied across multiple therapeutic areas. The strength of the collaboration in the identification of novel and robust targets is due to its innovative structure combining AstraZeneca’s scientific and disease-specific expertise with BenevolentAI’s AI-driven drug discovery platform and biomedical knowledge. As with the initial collaboration with AstraZeneca, the 2022 extension included an upfront payment on signing, as well as research funding alongside discovery, development and commercial milestones, in addition to tiered royalties on net sales of any commercialised products. SLE, or lupus, is a chronic autoimmune disease where the immune system mistakenly identifies the body’s own tissues as foreign. In people with lupus, the immune system creates autoantibodies to attack the body’s own tissues. These autoantibodies form immune complexes causing inflammation, pain and damage – often affecting the organs and joints in severe cases. Extreme fatigue and cognitive issues are also common, along with comorbidities including cardiovascular disease. Lupus disproportionately affects females and people of Asian, Black African and Caribbean heritage. Dr Anne Phelan, Chief Scientific Officer of BenevolentAI, said: “Following our recent success in the area of heart failure, I’m delighted that AstraZeneca has selected a novel target for SLE to enter its portfolio. The continued, fruitful efforts of our two companies working in collaboration will help bring potential new therapeutic options to lupus patients, whose quality of life is often severely limited by the disease.” Prof Maria Belvisi, SVP and Head of Research and Early Development Respiratory and Immunology at AstraZeneca said: “Our aim is to lead in lupus by continuing to discover and develop novel treatments that push the efficacy ceiling for patients, allowing more people to achieve remission. By combining our immunology disease area expertise and BenevolentAI’s AI-driven discovery platform, we are increasing our ability to identify new targets based on patient insights, complementing our portfolio of potential treatments for this debilitating disease.” Lees meer op: https://beursforum.be/viewtopic.php?f=3&t=1128&p=76121#p76121
SLE. bullish divergence on the rsi. Broke the 100 daily ema today. 30% rev increase in prelim reports. Stochastic rsi crossing. insane fundamentals. This I’ve bet the bag on it and am waiting for the definite moonshot
SLE will go to $5 from where it is now. Easy trade.
Looks like $SONG is hitting all the wrong notes, but fear not because it's time to dance to the beat of success with $SLE and $LIFFF this holiday season! For further stock market wisdom, check out [Recommended reading list](https://thetatitans.com/summary-of-theory/#recommended-reading).
Make sure to add $SLE, $LIFFF and $SONG to your watchlist - but also add Rich Dad Poor Dad and The Intelligent Investor from [Recommended reading list](https://thetatitans.com/summary-of-theory/#recommended-reading) for a double dose of profit potential! 💰 #optiontrading #winning